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Introduction
Prokaryotes inhabit many hostile environments that 
are often inaccessible to other organisms. Regardless of 
their environment, prokaryotes are able to adapt and 
adjust to the changing world by developing new tactics 
to promote survival. One of the systems constituting 
a natural defense mechanism is the ability to distinguish 
self from non‑self nucleic acids. Nucleic acids may be 
inserted into prokaryotic cells by infection, transduc‑
tion, conjugation, or transformation, and may have 
harmful effects. The defense mechanisms include the 
restriction‑modification, abortive infection, and sur‑
face exclusion systems, all of which act in an innate, 
non‑specific manner (Samson et al., 2013). However, 
a unique defense system involving clustered regularly 
interspaced palindromic repeats‑CRISPR‑associated 
proteins (CRISPR‑Cas) was reported recently. This 
system is present in most archaeal species and approxi‑
mately half of all bacterial species. A unique feature of 
the CRISPR‑Cas system is that it provides adaptive and 
hereditary immunity against foreign nucleic acids, mim‑
icking in some ways the immune systems of eukaryotes.
The first reports of the CRISPR‑Cas system originate 
from as early as 1987, but these repeat regions were not 
associated with a specific function (Ishino et al., 1987). 
In 2002, they were discovered in other bacteria and 
named CRISPR (Jansen et al., 2002). Since then, numer‑
ous roles of CRISPR‑Cas systems have been postulated, 
including chromosomal rearrangements, modulation 
of gene expression, replicon partitioning, and DNA 
repair (Babu et al., 2011; Jansen et al., 2002; Makarova 
et al., 2002; Mojica et al., 1995). Discovery of the simi‑
larity between some CRISPR spacer sequences and 
sequences from viruses and plasmids led to the sug‑
gestion that CRISPRs play roles in adaptive immunity 
against foreign nucleic acids (Makarova et al., 2006). 
Later, spacers homologous to chromosomal genes of the 
host were discovered (Bolotin et al., 2005; Mojica et al., 
2005), suggesting that, in addition to phage immunity, 
CRISPR‑Cas systems may play a role in autoimmun‑
ity or as a regulatory mechanisms (Sorek et al., 2008; 
Stern et al., 2010).
Components of the CRISPR-Cas system
The CRISPR‑Cas system comprises genomic 
(CRISPR) and proteomic (Cas) components. The geno‑ 
mic component is a DNA loci containing short frag‑
ments of targeted nucleic acid sequences (spacers) inter‑
spaced by short repeated sequences (repeats). These 
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spacer sequences can be of either foreign or self‑origin 
(Stern et al., 2010; Vercoe et al., 2013). The proteomic 
component is responsible for the incorporation of new 
template sequences, processing them into a form that 
enables base pairing with target nucleic acids, as well 
as for scanning and cleavage of target DNA or RNA. Of 
note, not all CRISPR‑Cas systems discovered to date are 
active (Haft et al., 2005; van der Ploeg, 2009).
Structure of the CRISPR-Cas system
The genomic component of the CRISPR‑Cas system 
is formed by a series of variable spacers, which in some 
cases share sequence similarity with viruses, plasmids, 
or bacteria. These regions are interspaced with repeat 
sequences that are identical or almost identical within 
a  single CRISPR cassette. The length of the repeat 
sequences varies between 25 and 40 nt, whereas the 
length of the spacer sequences varies between 21 and 
72 nt. As mentioned above, some spacers show high 
homology with foreign nucleic acids, but the origin of 
a significant percentage of spacers remains unknown. 
The sequence homology between the spacer and the 
target is the major determinant of nucleic acid degrada‑
tion of the target. Some bacterial species contain more 
than one CRISPR locus within their genome (Louwen 
et al., 2014). Depending on the specific bacterial spe‑
cies or strain, a CRISPR locus may contain from a few 
to several hundred repeat spacer units; however, most 
commonly, a  single CRISPR locus contains approxi‑
mately 50 units. The CRISPR repeat sequences play an 
important role during both the acquisition of new spac‑
ers and the transcription and maturation of CRISPR 
RNA (crRNA). Based on the sequence similarity, the 
CRISPR repeats are assigned into groups (Kunin et al., 
2007). These groups were taken into account in the cur‑
rent classification of CRISPR‑Cas systems (Makarova 
et al., 2011). Although most CRISPR arrays are located 
on chromosomal DNA, there are examples of CRISPRs 
located on plasmids (Godde and Bickerton, 2006). In 
general, CRISPR loci are flanked by A/T rich leader 
sequences containing promoter elements and binding 
sites for regulatory proteins (Jansen et al., 2002; Yosef 
et al., 2012).
CRISPR arrays are usually located in close proxim‑
ity to a set of genes encoding Cas proteins. Members 
of this large group of proteins are required for CRISPR 
activity and have multiple functions as nucleases, poly‑
merases, helicases, and nucleic acid binders. The exact 
number and types of Cas proteins depend on the spe‑
cific CRISPR‑Cas class.
Similar to other immune systems, the CRISPR‑Cas 
system requires differentiation between self and non‑
self species to avoid autoimmunity. The CRISPR array 
is the most susceptible to autoimmune events as it con‑
tains spacers used for target recognition. In most cases, 
the CRISPR‑Cas system deals with this problem by 
utilizing protospacer adjacent motifs (PAMs) (Sashital 
et al., 2012),which are present in the target DNA but 
not the CRISPR array. DNA cleavage occurs only if 
the correct PAM sequence is present (Jinek et al., 2012; 
Semenova et al., 2011; Westra et al., 2013). However, 
in type III CRISPR‑Cas systems the safety mechanism 
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is PAM‑independent and is based on the proximity of 
a repeat sequence to a spacer sequence in the CRISPR 
locus, which hinders its cleavage (Marraffini and 
Sontheimer, 2010).
The current classification of CRISPR‑Cas systems is 
based on the sequences of the cas genes, the sequences 
of the repeats within the CRISPR arrays, and the organ‑
ization of the cas operons (Makarova et al., 2011). The 
classification distinguishes three main types of CRISPR‑
Cas systems (types I–III). Each type is also divided 
into subtypes, including I‑A to I‑F, II‑A to II‑C, III‑A 
and III‑B. The cas1 and cas2 genes are common to all 
three CRISPR‑Cas types. The major criterion for clas‑
sification includes the presence or absence of certain 
Cas proteins. For example, the Cas3, Cas9, and Cas10 
proteins are hallmarks of CRISPR/Cas types I, II and 
III, respectively. Systems that do not have the specific 
hallmarks of types I–III are grouped as unclassified 
(type U). A description of the CRISPR‑Cas subtypes is 
provided in Table I.
Mode of action
Profound studies of the mode of action of the 
CRISPR‑Cas system revealed that the process can be 
divided into three distinct phases: (1) the acquisition 
of spacers following exposure to foreign nucleic acids, 
(2) the transcription of spacers and transcript process‑
ing to produce a crRNA that guides target recogni‑
tion, and (3) target recognition and cleavage. Figure 1 
shows a schematic overview of the CRISPR‑Cas mode 
of action, and each phase is discussed in detail below.
Spacer acquisition
The most important feature of the CRISPR/Cas sys‑
tem is its capacity to respond dynamically to external 
stimuli. This adaptation relies on the ability to insert 
fragments of foreign nucleic acids into the CRISPR 
array, such that they serve as a template for the gen‑
eration of crRNA, which mediates the subsequent 
Fig. 1. Scheme of CRISPR‑Cas system. S0, S1, S2, … , Sn stands for spacer sequences. R stands for repeat sequence.
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degradation of targeted nucleic acids. In this manner, 
bacteria are able to learn the patterns present in nucleic 
acids during invasion of foreign genetic elements. The 
mechanism responsible for the recognition, processing, 
and integration of new spacers has not been character‑
ized fully; nevertheless, a number of factors involved in 
the process were identified.
New spacers are incorporated into the leader end 
of the CRISPR array in an orderly manner (Barrangou 
et al., 2007; Pourcel et al., 2005). Such unilateral inser‑
tion of new spacers converts the CRISPR array into 
a timeline containing a chronological database of for‑
eign nucleic acid encounters. Prior to the incorporation 
of a new spacer sequence into the CRISPR array, for‑
eign nucleic acids must be recognized and fragmented. 
A study performed in Streptococcus thermophiles indi‑
cated that the restriction‑modification system can sup‑
ply the CRISPR‑Cas system with potential substrates for 
integration (Dupuis et al., 2013). However, several fac‑
tors are important for the incorporation of novel nucleic 
acids into the cell’s genome. For example, the presence 
of a PAM (Deveau et al., 2008) sequence flanking the 
protospacer sequence, is necessary for the selection 
of spacers (Mojica et al., 2009). A positively selected 
protospacer sequence is then processed into a precur‑
sor (Swarts et al., 2012). To enable integration of this 
precursor into the CRISPR array, the repeat adjacent to 
the leader end sequence is nicked at the 3’ ends of both 
of its strands, and the precursor is subsequently inte‑
grated between two single‑stranded repeat sequences 
(Díez‑Villaseñor et al., 2013). It has been hypothesized 
that an interaction between the leader sequence and 
Cas proteins ensures proper orientation of newly inte‑
grated spacers within the CRISPR array (Yosef et al., 
2012). The last step of spacer integration is reconstruc‑
tion of the second strands of the repeat; as a result, the 
repeat sequence is duplicated during the integration 
process (Yosef et al., 2012). In addition to PAM, other 
sequence motifs that affect the rate of spacer incorpora‑
tion were also discovered in proto spacers. An exam‑
ple of such a sequence motif is the acquisition affect‑ 
ing motif, which comprises a dinucleotide AA and is 
located at the 3’ end of a protospacer (Yosef et al., 2013).
In addition to genetic factors, the process of spacer 
acquisition also involves protein components. Among 
the many factors involved in spacer acquisition, the 
Cas1 and Cas2 proteins seem to be the most impor‑
tant. Both of these proteins are important for spacer 
integration (Yosef et al., 2012) and are conserved in all 
CRISPR‑Cas systems (Haft et al., 2005; Makarova et al., 
2011). A study in Escherichia coli showed that Cas1 and 
Cas2 form a protein complex that interacts with the 
CRISPR locus (Datsenko et al., 2012; Yosef et al., 2012). 
Despite the identification of a number of activities and 
structural motifs of these proteins (Babu et al., 2011; 
Beloglazova et al., 2008; Nam et al., 2012a; Reeks et al., 
2013; Wiedenheft et al., 2012; Wiedenheft et al., 2009), 
their exact function in spacer acquisition remains 
unknown. A side from Cas1 and Cas2, several other 
factors may also be involved in the CRISPR‑Cas adap‑
tation stage. In E. coli, the Cas1 protein interacts with 
housekeeping proteins involved in DNA maintenance, 
including the RecBCD and RuvB proteins (Babu et al., 
2011). Several recent findings also indicate the involve‑
ment of additional Cas proteins, namely, Cas3, Cas4, 
Csa1, and Csn2 (Arslan et al., 2013; Jackson et al., 2014; 
Makarova et al., 2006; Makarova et al., 2011; van der 
Oost et al., 2009; Zhang et al., 2012a). Csn2 is thought 
to be responsible for the recruitment of additional fac‑
tors and stabilization of DNA breaks in the CRISPR 
array during spacer acquisition (Arslan et al., 2013).
An interesting phenomenon linked with spacer 
acquisition has been described. Although one spacer is 
sufficient for target DNA degradation, a single CRISPR 
locus can contain multiple spacers originating from 
a single genetic entity. This finding led to the so‑called 
hypothesis of “primed spacer acquisition”, in which the 
presence of one spacer can trigger the acquisition of 
additional spacers from the same DNA target (Swarts 
et al., 2012). This primed acquisition can also occur in 
the presence of mismatches between the spacer and 
protospacer sequences that prevent the interference 
(Datsenko et al., 2012; Heler et al., 2014). It is thought 
that the role of primed spacer acquisition is to coun‑
ter possible evasion. The hypothesis that the effector 
complex slides across the target DNA was proposed to 
explain the mechanism of primed acquisition (Datsenko 
et al., 2012; Fineran et al., 2014; Li et al., 2014). This 
hypothesis states that, after a failed interference attempt, 
the effector complex recruits Cas1 and Cas2, and then 
slides along the target strand to find suitable PAMs that 
enable the acquisition of new spacers. However, this pro‑
posed mechanism has not yet been confirmed.
Transcript processing
Spacers within the CRISPR array cannot interfere 
directly with foreign nucleic acids and need to be tran‑
scribed. In most cases, transcription is initiated by the 
leader sequence located upstream of the CRISPR array. 
As a  result, a  long precursor transcript called a  pre‑
crRNA is created. Further processing of this transcript 
differs depending on the CRISPR‑Cas system type; 
however, a  notable exception has been described. In 
Neisseria spp., no pre‑crRNA transcript is generated; 
instead, the crRNAs are transcribed separately from 
promoters embedded within repeat sequences, and their 
5’ ends are formed by transcription rather than matu‑
ration (Zhang et al., 2013). Notably, these crRNAs can 
undergo type II processing (see below), although it is 
not required for their functionality (Zhang et al., 2013).
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In type I and III CRISPR‑Cas systems, initial pro‑
cessing of the pre‑crRNA is performed by Cas6 nucle‑
ase homologs carrying two repeat‑associated mysteri‑
ous protein domains (Reeks et al., 2013). Cleavage of 
the pre‑crRNA generates a product comprising a full 
spacer sequence flanked by repeat‑derived handles 
on both ends. In most cases, the 5’ handles are 8  nt 
(nucleotides) long (11nt in type I‑C systems (Nam et al., 
2012b) and 13 nt in I‑D systems (Scholz et al., 2013), 
whereas the 3’ handles have variable lengths depending 
on the specific CRISPR‑Cas type. In some types, the 
3’ handles form hairpin structures (Carte et al., 2010; 
Carte et al., 2008; Niewoehner et al., 2014; Wang et al., 
2011). In type I‑C systems, initial processing is per‑
formed by Cas5 rather than Cas6 (Garside et al., 2012; 
Nam et al., 2012b), whereas in other CRISPR‑Cas types, 
Cas5 is catalytically inactive and is thought to inter‑
act with the 5’ handle of the crRNA (Wiedenheft et al., 
2011). In most type I and type III systems, after initial 
processing, the crRNA is transferred to CRISPR ribo‑
nucleoprotein (crRNP) complexes for secondary pro‑
cessing (Hatoum‑Aslan et al., 2011). In types I‑A, I‑B, 
I‑C, and I‑D, this processing results in shortening of 
the 3’ handles. In both subtypes of type III, secondary 
processing generates two populations of products that 
differ in length by 6 nt (Hale et al., 2012; Zhang et al., 
2012b). In contrast to the systems mentioned above, 
types I‑E and I‑F do not utilize secondary processing. 
After initial cleavage by Cas6 or its homolog, the Cas6 
protein remains associated with the hairpin at the 3’ 
handle of the crRNA. Subsequently, this sub‑complex 
is incorporated into Cascade, the effector complex uti‑
lized by type I systems.
The mechanism of pre‑crRNA processing in type II 
systems differs from those of type I and type III sys‑
tems. First, an additional fragment encoding a  trans 
activating crRNA (tracrRNA) is transcribed from the 
CRISPR locus. The tracrRNA contains a 25 nt sequence 
complementary to the repeat sequences within the pre‑
crRNA. Initial processing involves hybridization of the 
tracrRNA and pre‑crRNA, and the hybrids are subse‑
quently digested by RNase III associated with Cas9 
(Deltcheva et al., 2011; Jinek et al., 2012). After cleavage, 
the hybrids attached to Cas9 undergo further trimming 
by an unidentified nuclease to yield functional, mature 
crRNA (Deltcheva et al., 2011).
Target recognition and degradation
Mature crRNAs are incorporated into crRNP com‑
plexes. Depending on the type of CRISPR‑Cas system, 
these effector complexes vary in their composition and 
mode of action; however, the general mechanism is 
common among types I–III. Initially, the crRNP com‑
plex scans nucleic acids for protospacer sequences. 
Base pairing between the crRNA spacer and the proto 
spacer begins in a 7–8 nt seed region (Semenova et al., 
2011). Further hybridization to the protospacer region 
results in formation of an R‑loop structure, in which the 
crRNA is paired with one of the DNA strands and the 
displaced DNA strand remains single‑stranded (Sashi‑
tal et al., 2012; Sorek et al., 2013). This structure triggers 
a conformational change in the crRNP complex, thereby 
initiating type‑dependent nuclease activity (Jore et al., 
2011; Spilman et al., 2013; Wiedenheft et al., 2011). 
During the degradation phase, to prevent the effec‑
tor complex from digesting its own CRISPR array, it is 
essential to distinguish between foreign and self DNA. 
In type I and type II CRISPR‑Cas systems, this safety 
mechanism is based on the presence of PAMs (Gasiu‑
nas et al., 2012; Jinek et al., 2012; Semenova et al., 2011; 
Westra et al., 2013). Within the targeted nucleic acids, 
the PAM sequence is localized in close proximity to the 
protospacer sequence, whereas the spacer sequence in 
the CRISPR array lacks this element; consequently, the 
CRISPR region is not cleaved. In type III CRISPR‑Cas 
systems, discrimination between self and foreign DNAs 
is PAM‑independent. In these systems, the 5’ handle of a 
crRNA interacts with a repeat sequence in the CRISPR 
locus. This interaction probably prevents nuclease 
recruitment, thereby preventing cleavage of self DNA 
(Marraffini and Sontheimer, 2010).
The effector complexes of type I and type III sys‑
tems share a significant level of structural similarity. 
The small subunits of these complexes include Csa5 and 
Cse2 in type I systems, and Csm2 and Cmr5 in type III 
systems. The large subunits include Cas8 homologs and 
Cas10 homologs in types  I and III, respectively. The 
effect or complexes of all subtypes of type I CRISPR‑Cas 
systems share significant similarities and are collectively 
referred to as Cascade complexes (Reeks et al., 2013). 
A typical Cascade complex consist of Cse1 (one subu‑
nit), Cse2 (two subunits), Cas5 (one subunit), Cas7 (six 
subunits), and Cas6 (one subunit) (Jore et al., 2011; van 
Duijn et al., 2012). The type I‑E Cascade complex from 
E. coli is the most well‑characterized of all CRISPR‑Cas 
systems. The backbone of the complex consists of six 
Cas7 units, along which the crRNA is positioned. The 
5’ and 3’ handles of the crRNA are anchored at opposite 
sides of the complex to Cas5 and Cas6, respectively. 
The Cse1 protein located at the 5’ crRNA end of the 
complex is responsible for the non‑specific interaction 
with DNA during initial target scanning (Jore et al., 
2011). This protein is also responsible for interaction 
with the PAM motif located at the 3’ end of the proto 
spacer (Sternberg et al., 2012), and this interaction is 
thought to trigger hybridization of the crRNA and tar‑
get DNA by destabilization of the DNA duplex (Sashital 
et al., 2012). In type I‑E systems, the seed region, which 
requires perfect hybridization for target degradation, 
is located at the 5’ end of the spacer (positions 1–5, 
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7, and 8) (Künne et al., 2014; Semenova et al., 2011). 
A  conformational change in the Cascade complex, 
linked with formation of the R‑loop, triggers recruit‑
ment of the Cas3 protein (Westra et al., 2012). Cas3 
possesses metal‑dependent nuclease and ATP‑depend‑
ent helicase activities (Beloglazova et al., 2011; Jackson 
et al., 2014; Mulepati and Bailey, 2011), and initial DNA 
cleavage occurs on the strand displaced during forma‑
tion of the R‑loop (Sinkunas et al., 2013). The subse‑
quent degradation of the target proceeds in an exonu‑
cleolytic manner from the 3’ to the 5’ end (Beloglazova 
et al., 2011; Westra et al., 2012). The second strand of 
the DNA is digested in both endonucleolytic and exo‑
nucleolytic manners (Beloglazova et al., 2011; Mulepati 
and Bailey, 2011; Westra et al., 2012). 
The mechanism of interference used by type  II 
CRISPR‑Cas systems differs from that of type  I sys‑
tems. In type II systems, interference depends on the 
Cas9‑RNP complex, the structure of which is rela‑
tively less intricate than those of other CRISPR types 
and includes Cas9 and a single guide RNA (sgRNA) 
(Jinek et al., 2014; Nishimasu et al., 2014). The sgRNA 
is a duplex of crRNA and tracrRNA (Jinek et al., 2012). 
Cas9 has two domains, an α‑helical recognition domain 
and a nuclease domain; the first of these domains is 
responsible for coordinating the guide RNA, and the 
second takes part in PAM recognition and target DNA 
cleavage. The nuclease domain actually comprises two 
individual nucleases, namely, RuvC and HNH (Nishi‑
masu et al., 2014). The interference process begins with 
the incorporation of a sgRNA into Cas9, which results 
in a  conformational change of Cas9 that enables the 
complex to bind DNA (Jinek et al., 2014). Subsequently, 
DNA scanning proceeds in a similar manner to that 
in type I systems. The PAM motif of type II systems is 
located at the 5’ end of the proto spacer (Deveau et al., 
2008; Mojica et al., 2009). Recognition of this motif is 
considered to lead to displacement of the DNA strand 
and formation of the R‑loop. Base pairing between the 
spacer and proto spacer starts from a 12 nt seed region 
(Jiang et al., 2013; Sternberg et al., 2014). Each strand 
of the target DNA is digested by a different nuclease 
domain of Cas9 protein; specifically, the HNH domain 
cleaves the strand hybridized with crRNA, and the 
RuvC domain cleaves the displaced strand (Jinek et al., 
2012; Jinek et al., 2014).
Type III CRISPR‑Cas effector complexes resemble 
those of the type I Cascade complex. The backbone of 
the type III crRNP complex is composed of multiple 
Csm3 (type III‑A) or Cmr4 (type III‑B) proteins (Rouil‑
lon et al., 2013; Spilman et al., 2013; Staals et al., 2013). 
Like type I CRISPR‑Cas effector complexes, the crRNA 
is positioned along the backbone in type III complexes 
(Rouillon et al., 2013). Parallel to the backbone, the 
small subunits (Csm2 or Cmr5) form a secondary string 
connecting the two ends of the complex. The Csm4 
(type III‑A) or Cmr3 (type III‑B) protein is located at 
the 5’ end of the crRNA and is bound to the large subu‑
nit (Csm1 or Cmr2, respectively). Together with the 
Cmr6 protein, Csm5 or Cmr1 is located at the 3’ end 
of the crRNA and bound to a small subunit (Csm2 or 
Cmr5). Functioning of type III systems is not as well‑
characterized as that of other types, but some important 
differences have been described. As mentioned earlier, 
in type III‑A systems, discrimination between self and 
non‑self DNA proceeds in a PAM‑independent manner 
(Rouillon et al., 2013), and the large subunit (Csm1) 
is thought to take part in the discrimination process 
(Hatoum‑Aslan et al., 2014). The presence of a  seed 
sequence within the spacer sequence was proposed 
(Hatoum‑Aslan et al., 2014) but not confirmed fully. 
Type  III‑B systems are unique among other CRISPR 
types because they target RNA rather than DNA (Hale 
et al., 2009); however, there are examples of type III‑B 
systems targeting plasmid DNA in vivo (Deng et al., 
2013). Most type III‑B effector complexes comprise six 
proteins (Cmr1‑6) (Gasiunas et al., 2014); however, in 
Sulfolobus solfataricus, these effector complexes con‑
tain an additional protein (Cmr7) (Zhang et al., 2012b). 
Recognized target RNA is cleaved at regular intervals 
in the 3’ to 5’ direction (Staals et al., 2013). This diges‑
tion pattern indicates the presence of multiple active 
sites within the backbone of the Cmr complex (Staals 
et al., 2013), which is composed of multiple subunits of 
Cmr4 and Cmr5.
Other functions of the CRISPR-Cas system
Recognition and degradation of invading nucleic 
acids is a major function of the CRISPR‑Cas system; 
however, several studies showed that it may have 
additional roles. One of the intriguing features of the 
CRISPR‑Cas system is the presence of spacers that are 
complementary to bacterial genes (Bolotin et al., 2005; 
Horvath et al., 2009; Mojica et al., 2005; Shah et al., 
2009). This feature suggests the possibility of recogni‑
tion and cleavage of self nucleic acids and, consequently, 
may be considered a form of autoimmunity (Stern et al., 
2010; van der Ploeg, 2009). However, it is worth noting 
that CRISPR‑Cas systems containing self‑targeting ele‑
ments often lack some cas genes or are non‑functional 
(Haft et al., 2005; Stern et al., 2010; van der Ploeg, 2009). 
None the less, the presence of autoimmunity within 
CRISPR‑Cas systems does not exclude their regulatory 
roles, and alteration of cas gene expression in response 
to stress is a commonly observed phenomenon (Perez‑
Rodriguez et al., 2011; Viswanathan et al., 2007). There 
are also several examples of Cas proteins involved in 
the regulation of bacterial virulence. Francisella novi­
cida utilizes a CRISPR‑Cas system to evade recogni‑
tion by host pattern recognition receptors (Sampson 
CRISPR‑Cas3 199
et al., 2013); this is achieved by down‑regulation of 
the mRNA coding for bacterial lipoprotein, a  sur‑
face protein that is recognized by the host’s Toll‑like 
receptor‑2. Down‑regulation of the mRNA encoding 
bacterial lipoprotein weakens the Toll‑like receptor‑2 
induced pro‑inflammatory cytokine response. Neis­
seria meningitides and Campylobacter jejuni employ 
Cas9 for the modulation of virulence (Louwen et al., 
2013; Sampson et al., 2013); however, in these species, 
the exact mechanism of action has not been deciphered 
fully. Furthermore, in Legionella pneumophila, Cas2 
plays an important role in intracellular survival and 
replication in amoebae via an unidentified mechanism 
(Gunderson and Cianciotto, 2013).
CRISPR-Cas-based technology
The first practical application of CRISPR‑Cas sys‑
tems was typing of bacterial diversity (Groenen et al., 
1993; Kamerbeek et al., 1997). Several typing methods 
were developed based on CRISPR locus size, spacer 
content of a given locus, or point mutations within spe‑
cific spacer and/or repeat sequences (Shariat and Dud‑
ley, 2014). Increasing knowledge of the mechanisms of 
action of CRISPR‑Cas opened new avenues for applica‑
tions of these systems. It became clear that easily repro‑
grammable, precisely controllable, sequence‑specific 
nucleic acid cleavage is useful for molecular biology‑
based studies. To date, the most well‑developed methods 
are based on the type II CRISPR‑Cas effector complex, 
mainly because of its simplicity, in that it consists of 
Cas9 and sgRNA only (Jinek et al., 2012). In addition, 
DNA cleavage by Cas9 is very efficient (Gasiunas et al., 
2012), and target recognition can be programmed by 
exchanging the sgRNA guiding sequence (Jinek et al., 
2012). The limitation of the application of this effector 
complex for molecular biology studies is the require‑
ment for a PAM sequence within the desired target.
Eukaryotic DNA repair mechanisms can be used in 
combination with the CRISPR‑Cas9 system can be used 
as a genome editing tool. Introduction of a crRNA‑tracr‑
RNA‑Cas9 unit into eukaryotic cells results in sequence‑
specific DNA cleavage, and the cleaved strands undergo 
repair by an endogenous mechanism in the cell. Homol‑
ogous recombination or non‑homologous end joining of 
previously cleaved DNA enables genome editing (Cong 
et al., 2013; Jinek et al., 2013; Mali et al., 2013b). In addi‑
tion to dsDNA cleavage, Cas9‑based systems can also 
be used for other purposes, such as nicking or binding 
DNA, which can be achieved by introducing mutations 
within the active sites of the Cas9 nuclease domains 
(HNH and RuvC) (Mali et al., 2013a). The advantage 
of nicking DNA over blunt cutting is the possibility to 
create defined overhangs, thereby enabling direction of 
the specific recombination event (Mali et al., 2013a). 
Mutation of both the HNH and RuvC domains con‑
verts Cas9 into a RNA‑guided dsDNA binding protein 
(dCas9), and programming dCas9 to bind to a specific 
promoter region can efficiently prevent transcription of 
a gene of interest (Bikard et al., 2013). 
The use of Cas9 fused with other proteins also ena‑
bles its employment for other applications. When fused 
with an activator domain, dCas9 enhances transcription 
(Bikard et al., 2013); for example, dCas9 fused with the 
ω subunit of bacterial RNA polymerase recruits other 
subunits of the polymerase (Opalka et al., 2010). Fur‑
thermore, fusion of Cas9 with green fluorescent protein 
enables its use in live cell imaging (Chen et al., 2013). 
It could be speculated that other CRISPR‑Cas modules 
will be used in molecular biology applications in the 
future, such as targeting of RNA by type III‑B systems.
Concluding remarks
Since its discovery, the CRISPR‑Cas system has been 
an intriguing object of study. Before the identification 
of the functionality of this system, adaptive immunity 
was considered to be associated exclusively with eukar‑
yotic organisms (Goren et al., 2012). Adaptations of the 
CRISPR‑Cas system in response to environmental con‑
ditions are hereditary; therefore, this system is a fine 
example of Lamarckian inheritance (Koonin and Wolf, 
2009). Enhanced understanding of the mechanism of 
action of the CRISPR‑Cas system enabled the develop‑
ment of new tools for genome engineering that are effi‑
cient alternatives to transcription activator‑like effector 
nucleases (Boch et al., 2009) and zinc‑finger nucleases 
(Bibikova et al., 2003). The CRISPR‑Cas system was also 
used to build phage resistance in an industrial strain of 
Streptococcus thermophiles (Barrangou et al., 2013). This 
application is of significant value to microorganism‑
based industries, such as the dairy and biopharmaceuti‑
cal markets. Certainly, new CRISPR‑Cas‑based meth‑
ods will be developed in the future. Despite intensive 
research during recent years, many questions concern‑
ing the mode of action and possible applications of the 
CRISPR‑Cas system remain unanswered.
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